Aurora kinase inhibitors as anticancer molecules

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1799, Issue 10-12, 2010, Pages 829-839

  Katayama, Hiroshi ^a   Sen, Subrata ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aurora kinase; Aurora kinase inhibitor; Cancer therapy; Chromosomal instability; Mitosis

Indexed keywords

2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ABELSON KINASE; ADENOSINE TRIPHOSPHATE; ALPHA 1 ANTITRYPSIN; ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DANUSERTIB; HESPERADIN; HISTONE H3; MESSENGER RNA; MLN 8237; MYC PROTEIN; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PROTEIN P21; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RAS PROTEIN; RITUXIMAB; SCAFFOLD PROTEIN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VE 465; VE 645; ZM 447437;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ATYPICAL CHRONIC MYELOID LEUKEMIA; BLOOD TOXICITY; BREAST CANCER; BREAST CARCINOMA; CARBOXY TERMINAL SEQUENCE; CENTROSOME; CHRONIC MYELOID LEUKEMIA; COLON CARCINOGENESIS; COLORECTAL CANCER; CYTOKINESIS; ENZYME SUBSTRATE COMPLEX; GENE REGULATORY NETWORK; HUMAN; LIVER CELL CARCINOMA; MITOSIS; NEOPLASM; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; REVIEW; T CELL LEUKEMIA; YEAST;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOSIS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 78649864566     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2010.09.004     Document Type: Review

References (114)

1. Gautschi O., Heighway J., Mack P.C., Purnell P.R., Lara P.N., Gandara D.R. Aurora kinases as anticancer drug targets. Clin. Cancer Res. 2008, 14:1639-1648.
2. Sharma S.V., Fischbach M.A., Haber D.A., Settleman J. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin. Cancer Res. 2006, 12:4392-4395.
3. Pérez de Castro I., de Cárcer G., Malumbres M. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis 2007, 28:899-912.
4. Keen N., Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 2004, 4:927-936.
5. Fu J., Bian M., Jiang Q., Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol. Cancer Res. 2007, 5:1-10.
6. Garber K. Divide and conquer: new generation of drugs targets mitosis. J. Natl Cancer Inst. 2005, 97:874-876.
7. Carmena M., Ruchaud S., Earnshaw W.C. Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins. Curr. Opin. Cell Biol. 2009, 21:796-805.
8. Vader G., Lens S.M. The Aurora kinase family in cell division and cancer. Biochim. Biophys. Acta 2008, 1786:60-72.
9. Ruchaud S., Carmena M., Earnshaw W.C. Chromosomal passengers: conducting cell division. Nat. Rev. Mol. Cell Biol. 2007, 8:798-812.
10. Bayliss R., Sardon T., Vernos I., Conti E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol. Cell 2003, 12:851-862.
11. Eyers P.A., Erikson E., Chen L.G., Maller J.L. A novel mechanism for activation of the protein kinase Aurora A. Curr. Biol. 2003, 13:691-697.
12. Jeyaprakash A.A., Klein U.R., Lindner D., Ebert J., Nigg E.A., Conti E. Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell 2007, 131:271-285.
13. Adams R.R., Wheatley S.P., Gouldsworthy A.M., Kandels-Lewis S.E., Carmena M., Smythe C., Gerloff D.L., Earnshaw W.C. INCENP binds the Aurora-related kinase AIRK2 and is required to target it to chromosomes, the central spindle and cleavage furrow. Curr. Biol. 2000, 10:1075-1078.
14. Fu J., Bian M., Liu J., Jiang Q., Zhang C. A single amino acid change converts Aurora-A into Aurora-B-like kinase in terms of partner specificity and cellular function. Proc. Natl Acad. Sci. USA 2009, 106:939-944.
15. Hans F., Skoufias D.A., Dimitrov S., Margolis R.L. Molecular distinctions between Aurora A and B: a single residue change transforms Aurora A into correctly localized and functional Aurora B. Mol. Biol. Cell 2009, 20:3491-3502.
16. Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S., Novotny M., Slamon D.J., Plowman G.D. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998, 17:3052-3065.
17. Zhou H., Kuang J., Zhong L., Kuo W.L., Gray J.W., Sahin A., Brinkley B.R., Sen S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. 1998, 20:189-193.
18. Ota T., Suto S., Katayama H., Han Z.B., Suzuki F., Maeda M., Tanino M., Terada Y., Tatsuka M. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res. 2002, 62:5168-5177.
19. Macůrek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R., Freire R., Clouin C., Taylor S.S., Yaffe M.B., Medema R.H. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008, 455:119-123.
20. Seki A., Coppinger J.A., Jang C.Y., Yates J.R., Fang G. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 2008, 320:1655-1658.
21. Katayama H., Sasai K., Kloc M., Brinkley B.R., Sen S. Aurora kinase-A regulates kinetochore/chromatin associated microtubule assembly in human cells. Cell Cycle 2008, 7:2691-2704.
22. Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genet. 2004, 36:55-62.
23. Liu Q., Kaneko S., Yang L., Feldman R.L., Nicosia S.V., Chen J., Cheng J.Q. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J. Biol. Chem. 2004, 279:52175-52182.
24. Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A., Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J. Biol. Chem. 2004, 279:19643-19648.
25. Ryser S., Dizin E., Jefford C.E., Delaval B., Gagos S., Christodoulidou A., Krause K.H., Birnbaum D., Irminger-Finger I. Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2. Cancer Res. 2009, 69:1125-1134.
26. Yang H., Ou C.C., Feldman R.L., Nicosia S.V., Kruk P.A., Cheng J.Q. Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res. 2004, 64:463-467.
27. Dar A.A., Belkhiri A., El-Rifai W. The Aurora kinase A regulates GSK-3beta in gastric cancer cells. Oncogene 2009, 28:866-875.
28. Briassouli P., Chan F., Savage K., Reis-Filho J.S., Linardopoulos S. Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res. 2007, 67:1689-1695.
29. Irelan J.T., Murphy T.J., DeJesus P.D., Teo H., Xu D., Gomez-Ferreria M.A., Zhou Y., Miraglia L.J., Rines D.R., Verma I.M., Sharp D.J., Tergaonkar V., Chanda S.K. A role for IkappaB kinase 2 in bipolar spindle assembly. Proc. Natl Acad. Sci. USA 2007, 104:16940-16945.
30. Wu J.C., Chen T.Y., Yu C.T., Tsai S.J., Hsu J.M., Tang M.J., Chou C.K., Lin W.J., Yuan C.J., Huang C.Y. Identification of V23RalA-Ser194 as a critical mediator for Aurora-A-induced cellular motility and transformation by small pool expression screening. J. Biol. Chem. 2005, 280:9013-9022.
31. Lim K.H., Brady D.C., Kashatus D.F., Ancrile B.B., Der C.J., Cox A.D., Counter C.M. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol. Cell. Biol. 2010, 30:508-523.
32. Bee C., Moshnikova A., Mellor C.D., Molloy J., Koryakina Y., Stieglitz B., Khokhlatchev A., Herrmann C. The growth and tumor suppressor novel ras effector 1A (NORE1A) is a regulatory node between ras signaling and microtubule nucleation. J. Biol. Chem. 2010, [Epub ahead of print].
33. Otto T., Horn S., Brockmann M., Eilers U., Schüttrumpf L., Popov N., Kenney A.M., Schulte J.H., Beijersbergen R., Christiansen H., Berwanger B., Eilers M. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009, 15:67-78.
34. Maris J.M., Morton C.L., Gorlick R., Kolb E.A., Lock R., Carol H., Keir S.T., Reynolds C.P., Kang M.H., Wu J., Smith M.A., Houghton P.J. Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr. Blood Cancer 2010, [Epub ahead of print].
35. Lapenna S., Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 2009, 8:547-566.
36. Ditchfield C., Johnson V.L., Tighe A., Ellston R., Haworth C., Johnson T., Mortlock A., Keen N., Taylor S.S. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 2003, 161:267-280.
37. Cheung C.H., Coumar M.S., Hsieh H.P., Chang J.Y. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin. Investig. Drugs 2009, 18:379-398.
38. Pérez Fidalgo J.A., Roda D., Roselló S., Rodríguez-Braun E., Cervantes A. Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. Clin. Transl. Oncol. 2009, 11:787-798.
39. Hauf S., Cole R.W., LaTerra S., Zimmer C., Schnapp G., Walter R., Heckel A., van Meel J., Rieder C.L., Peters J.M. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. 2003, 161:281-294.
40. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., Graham J.A., Demur C., Hercend T., Diu-Hercend A., Su M., Golec J.M., Miller K.M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 2004, 10:262-267.
41. R.A. Walter, G.J. Heckel, J. Roth, G. Kley, M. Schnapp, J.C.A. Lenter, W. van Meel Spevak, and U. Weyer-Czernilofsky, inventors and assignees. Sulfonylamino substituted 3-(aminomethylide)-2-indolinones as cell proliferation inhibitors. Patent Cooperation Treaty, (2002), International Publication Number WO 02/36564.
42. Scutt P.J., Chu M.L., Sloane D.A., Cherry M., Bignell C.R., Williams D.H., Eyers P.A. Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks. J. Biol. Chem. 2009, 284:15880-15893.
43. Gizatullin F., Yao Y., Kung V., Harding M.W., Loda M., Shapiro G.I. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res. 2006, 66:7668-7677.
44. Dreier M.R., Grabovich A.Z., Katusin J.D., Taylor W.R. Short and long-term tumor cell responses to Aurora kinase inhibitors. Exp. Cell Res. 2009, 315:1085-1099.
45. Kojima K., Konopleva M., Tsao T., Nakakuma H., Andreeff M. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood 2008, 112:2886-2895.
46. Li M., Jung A., Ganswindt U., Marini P., Friedl A., Daniel P.T., Lauber K., Jendrossek V., Belka C. Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways. Biochem. Pharmacol. 2010, 79:122-129.
47. Sun C., Chan F., Briassouli P., Linardopoulos S. Aurora kinase inhibition downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic agents. Biochem. Biophys. Res. Commun. 2007, 352:220-225.
48. Dar A.A., Belkhiri A., Ecsedy J., Zaika A., El-Rifai W. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res. 2008, 68:8998-9004.
49. Cheok C.F., Kua N., Kaldis P., Lane D.P. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ. 2010, [Epub ahead of print].
50. Ikezoe T., Yang J., Nishioka C., Yokoyama A. p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells. Int. J. Hematol. 2010, 91:69-77.
51. Lin Y.G., Immaneni A., Merritt W.M., Mangala L.S., Kim S.W., Shahzad M.M., Tsang Y.T., Armaiz-Pena G.N., Lu C., Kamat A.A., Han L.Y., Spannuth W.A., Nick A.M., Jr C.N., Landen K.K.Wong, Gray M.J., Coleman R.L., Bodurka D.C., Brinkley W.R., Sood A.K. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin. Cancer Res. 2008, 14:5437-5446.
52. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., Milanov Z.V., Atteridge C.E., Biggs W.H., Edeen P.T., Floyd M., Ford J.M., Grotzfeld R.M., Herrgard S., Insko D.E., Mehta S.A., Patel H.K., Pao W., Sawyers C.L., Varmus H., Zarrinkar P.P., Lockhart D.J. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl Acad. Sci. USA 2005, 102:11011-11016.
53. Shah N.P., Skaggs B.J., Branford S., Hughes T.P., Nicoll J.M., Paquette R.L., Sawyers C.L. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 2007, 117:2562-2569.
54. Huang X.F., Luo S.K., Xu J., Li J., Xu D.R., Wang L.H., Yan M., Wang X.R., Wan X.B., Zheng F.M., Zeng Y.X., Liu Q. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 2008, 111:2854-2865.
55. Evans R., Naber C., Steffler T., Checkland T., Keats J., Maxwell C., Perry T., Chau H., Belch A., Pilarski L., Reiman T. Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk. Lymphoma 2008, 49:559-569.
56. Young M.A., Shah N.P., Chao L.H., Seeliger M., Milanov, W.H.3rd.Biggs, D.K.Treiber, H.K.Patel, P.P.Zarrinkar, D.J.Lockhart, C.L.Sawyers, and J.Kuriyan Z.V. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006, 66:1007-1014.
57. Giles F.J., Cortes J., Jones D., Bergstrom D., Kantarjian H., Freedman S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109:500-502.
58. Papayannidis C., Lacobucci L., Soverini S., Paolini S., Santucci S., Cilloni D., Messa F., Pane F., Meneghini V., Giannoulia P., Ottaviani E., Testoni N., Lama B., Pantaleo M., Baccarani M., Martinelli G. Innovative phase I-II study of concomitant and consecutive treatment with Dasatinib and MK-0457 in refractory Ph+ CML and ALL patients. AACR, Abstract meetings 2009.
59. Sanchez-Guijo F.M., Lopez-Jimenez J., Gonzalez T., Santamaría C., González M., Del Cañizo M.C. Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia. Leuk. Res. 2009, 33:20-22.
60. Lin Z.Z., Hsu H.C., Hsu C.H., Yeh P.Y., Huang C.Y., Huang Y.F., Chen T.J., Kuo S.H., Hsu C., Hu F.C., Jeng Y.M., Chung Y., Cheng A.L. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J. Hepatol. 2009, 50:518-527.
61. Jeng Y.M., Peng S.Y., Lin C.Y., Hsu H.C. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin. Cancer Res. 2004, 10:2065-2071.
62. Sistayanarain A., Tsuneyama K., Zheng H., Takahashi H., Nomoto K., Cheng C., Murai Y., Tanaka A., Takano Y. Expression of Aurora-B kinase and phosphorylated histone H3 in hepatocellular carcinoma. Anticancer Res. 2006, 26:3585-3593.
63. Scharer C.D., Laycock N., Osunkoya A.O., Logani S., McDonald J.F., Benigno B.B., Moreno C.S. Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J. Transl. Med. 2008, 6:79-91.
64. Akahane D., Tauchi T., Okabe S., Nunoda K., Ohyashiki K. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies. Cancer Sci. 2008, 99:1251-1257.
65. Fancelli D., Berta D., Bindi S., Cameron A., Cappella P., Carpinelli P., Catana C., Forte B., Giordano P., Giorgini M.L., Mantegani S., Marsiglio A., Meroni M., Moll J., Pittalà V., Roletto F., Severino D., Soncini C., Storici P., Tonani R., Varasi M., Vulpetti A., Vianello P. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J. Med. Chem. 2005, 48:3080-3084.
66. Fancelli D., Moll J., Varasi M., Bravo R., Artico R., Berta D., Bindi S., Cameron A., Candiani I., Cappella P., Carpinelli P., Croci W., Forte B., Giorgini M.L., Klapwijk J., Marsiglio A., Pesenti E., Rocchetti M., Roletto F., Severino D., Soncini C., Storici P., Tonani R., Zugnoni P., Vianello P. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J. Med. Chem. 2006, 49:7247-7251.
67. Carpinelli P., Ceruti R., Giorgini M.L., Cappella P., Gianellini L., Croci V., Degrassi A., Texido G., Rocchetti M., Vianello P., Rusconi L., Storici P., Zugnoni P., Arrigoni C., Soncini C., Alli C., Patton V., Marsiglio A., Ballinari D., Pesenti E., Fancelli D., Moll J. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol. Cancer Ther. 2007, 6:3158-3168.
68. Modugno M., Casale E., Soncini C., Rosettani P., Colombo R., Lupi R., Rusconi L., Fancelli D., Carpinelli P., Cameron A.D., Isacchi A., Moll J. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res. 2007, 67:7987-7990.
69. Gontarewicz A., Balabanov S., Keller G., Colombo R., Graziano A., Pesenti E., Benten D., Bokemeyer C., Fiedler W., Moll J., Brümmendorf T.H. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008, 111:4355-4364.
70. Benten D., Keller G., Quaas A., Schrader J., Gontarewicz A., Balabanov S., Braig M., Wege H., Moll J., Lohse A.W., Brummendorf T.H. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 2009, 11:934-944.
71. Cohen R.B., Jones S.F., Aggarwal C., von Mehren M., Cheng J., Spigel D.R., Greco F.A., Mariani M., Rocchetti M., Ceruti R., Comis S., Laffranchi B., Moll J., Burris H.A. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15:6694-6701.
72. Steeghs N., Eskens F.A., Gelderblom H., Verweij J., Nortier J.W., Ouwerkerk J., van Noort C., Mariani M., Spinelli R., Carpinelli P., Laffranchi B., de Jonge M.J. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J. Clin. Oncol. 2009, 27:5094-5101.
73. Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O., Chen W., Galvin K.M., Hoar K.M., Huck J.J., LeRoy P.J., Ray E.T., Sells T.B., Stringer B., Stroud S.G., Vos T.J., Weatherhead G.S., Wysong D.R., Zhang M., Bolen J.B., Claiborne C.F. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc. Natl Acad. Sci. USA 2007, 104:4106-4111.
74. Hoar K., Chakravarty A., Rabino C., Wysong D., Bowman D., Roy N., Ecsedy J.A. MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol. Cell. Biol. 2007, 27:4513-4525.
75. Wysong D.R., Chakravarty A., Hoar K., Ecsedy J.A. The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle 2009, 8:876-888.
76. Shang X., Burlingame S.M., Okcu M.F., Ge N., Russell H.V., Egler R.A., David R.D., Vasudevan S.A., Yang J., Nuchtern J.G. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol. Cancer Ther. 2009, 8:2461-2469.
77. Huck J.J., Zhang M., McDonald A., Bowman D., Hoar K.M., Stringer B., Ecsedy J., Manfredi M.G., Hyer M.L. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol. Cancer Res. 2010, 8:373-384.
78. Tomita M., Mori N. Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro. Cancer Sci. 2010, [Epub ahead of print].
79. Zhang M., Huck J., Hyer M., Ecsedy J., Manfredi M. Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. ASCO meeting. 2009.
80. Mortlock A.A., Foote K.M., Heron N.M., Jung F.H., Pasquet G., Lohmann J.J., Warin N., Renaud F., De Savi C., Roberts N.J., Johnson T., Dousson C.B., Hill G.B., Perkins D., Hatter G., Wilkinson R.W., Wedge S.R., Heaton S.P., Odedra R., Keen N.J., Crafter C., Brown E., Thompson K., Brightwell S., Khatri L., Brady M.C., Kearney S., McKillop D., Rhead S., Parry T., Green S. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J. Med. Chem. 2007, 50:2213-2224.
81. Grundy M., Seedhouse C., Shang S., Richardson J., Russell N., Pallis M. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Mol. Cancer Ther. 2010, 9:661-672.
82. Mortlock A.A., Boyle F.T., Green S. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin. Cancer Res. 2007, 13:3682-3688.
83. Wilkinson R.W., Odedra R., Heaton S.P., Wedge S.R., Keen N.J., Crafter C., Foster J.R., Brady M.C., Bigley A., Brown E., Byth K.F., Barrass N.C., Mundt K.E., Foote K.M., Heron N.M., Jung, Mortlock, F.T.Boyle, and S.Green F.H.A.A. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin. Cancer Res. 2007, 13:3682-3688.
84. Tao Y., Zhang P., Girdler F., Frascogna V., Castedo M., Bourhis J., Kroemer G., Deutsch E. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 2008, 27:3244-3255.
85. Gully C.P., Zhang F., Chen J., Yeung J.A., Velazquez-Torres G., Wang E., Yeung S.C., Lee M.H. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol. Cancer 2010, 9:42.
86. Oke A., Pearce D., Wilkinson R.W., Crafter C., Odedra R., Cavenagh J., Fitzgibbon J., Lister A.T., Joel S., Bonnet D. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 2009, 69:4150-4158.
87. Tanaka S., Arii S. Medical treatments: in association or alone, their role and their future perspectives: novel molecular-targeted therapy for hepatocellular carcinoma. J. Hepatobiliary Pancreat. Surg. 2009, [Epub ahead of print].
88. Yang J., Ikezoe T., Nishioka C., Tasaka T., Taniguchi A., Kuwayama Y., Komatsu N., Bandobashi K., Togitani K., Koeffler H.P., Taguchi H., Yokoyama A. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007, 110:2034-2040.
89. Evans R.P., Naber C., Steffler T., Checkland T., Maxwell C.A., Keats J.J., Belch A.R., Pilarski L.M., Lai R., Reiman T. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br. J. Haematol. 2008, 140:295-302.
90. Ikezoe T., Takeuchi T., Yang J., Adachi Y., Nishioka C., Furihata M., Koeffler H.P., Yokoyama A. Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab. Invest. 2009, 89:1364-1373.
91. Nair J.S., de Stanchina E., Schwartz G.K. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin. Cancer Res. 2009, 15:2022-2030.
92. Tao Y., Leteur C., Calderaro J., Girdler F., Zhang P., Frascogna V., Varna M., Opolon P., Castedo M., Bourhis J., Kroemer G., Deutsch E. The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle 2009, 8:3172-3181.
93. Schellens J.H., Boss D., Witteveen P.O., Zandvliet A., Beijnen J.H., Voogel-Fuchs M., Morris C., Wilson D., Voest E.E. Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. ASCO Annual Meeting 2006.
94. Oslob J.D., Romanowski M.J., Allen D.A., Baskaran S., Bui M., Elling R.A., Flanagan W.M., Fung A.D., Hanan E.J., Harris S., Heumann S.A., Hoch U., Jacobs J.W., Lam J., Lawrence C.E., McDowell R.S., Nannini M.A., Shen W., Silverman J.A., Sopko M.M., Tangonan B.T., Teague J., Yoburn J.C., Yu C.H., Zhong M., Zimmerman K.M., O'Brien T., Lew W. Discovery of a potent and selective aurora kinase inhibitor. Bioorg. Med. Chem. Lett. 2008, 18:4880-4884.
95. Stolz A., Vogel C., Schneider V., Ertych N., Kienitz A., Yu H., Bastians H. Pharmacologic abrogation of the mitotic spindle checkpoint by an indolocarbazole discovered by cellular screening efficiently kills cancer cells. Cancer Res. 2009, 69:3874-3883.
96. VanderPorten E.C., Taverna P., Hogan J.N., Ballinger M.D., Flanagan W.M., Fucini R.V. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol. Cancer Ther. 2009, 8:930-939.
97. Arbitrario J.P., Belmont B.J., Evanchik M.J., Flanagan W.M., Fucini R.V., Hansen S.K., Harris S.O., Hashash A., Hoch U., Hogan J.N., Howlett A.R., Jacobs J.W., Lam J.W., Ritchie S.C., Romanowski M.J., Silverman J.A., Stockett D.E., Teague J.N., Zimmerman K.M., Taverna P. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother. Pharmacol. 2010, 65:707-717.
98. Anderson K., Lai Z., McDonald O.B., Stuart J.D., Nartey E.N., Hardwicke M.A., Newlander K., Dhanak D., Adams J., Patrick D., Copeland R.A., Tummino P.J., Yang J. Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. Biochem. J. 2009, 420:259-265.
99. Hardwicke M.A., Oleykowski C.A., Plant R., Wang J., Liao Q., Moss K., Newlander K., Adams J.L., Dhanak D., Yang J., Lai Z., Sutton D., Patrick D. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol. Cancer Ther. 2009, 8:1808-1817.
100. Howard S., Berdini V., Boulstridge J.A., Carr M.G., Cross D.M., Curry J., Devine L.A., Early T.R., Fazal L., Gill A.L., Heathcote M., Maman S., Matthews J.E., McMenamin R.L., Navarro E.F., O'Brien M.A., O'Reilly M., Rees D.C., Reule M., Tisi D., Williams G., Vinković M., Wyatt P.G. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J. Med. Chem. 2009, 52:379-388.
101. Curry J., Angove H., Fazal L., Lyons J., Reule M., Thompson N., Wallis N. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle 2009, 8:1921-1929.
102. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., Taylor K., Herrmann R., Seymour J.F., Arthur C., Joske D., Lynch K., Hughes T. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102:276-283.
103. Goldman J.M., Melo J.V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J. Med. 2003, 349:1451-1464.
104. Weisberg E., Manley P.W., Cowan-Jacob S.W., Hochhaus A., Griffin J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 2007, 7:345-356.
105. Adrián F.J., Ding Q., Sim T., Velentza A., Sloan C., Liu Y., Zhang G., Hur W., Ding S., Manley P., Mestan J., Fabbro D., Gray N.S. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2006, 2:95-102.
106. Zhang J., Adrián F.J., Jahnke W., Cowan-Jacob S.W., Li A.G., Iacob R.E., Sim T., Powers J., Dierks C., Sun F., Guo G.R., Ding Q., Okram B., Choi Y., Wojciechowski A., Deng X., Liu G., Fendrich G., Strauss A., Vajpai N., Grzesiek S., Tuntland T., Liu Y., Bursulaya B., Azam M., Manley P.W., Engen J.R., Daley G.Q., Warmuth M., Gray N.S. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010, 463:501-506.
107. Barnett S.F., Defeo-Jones D., Fu S., Hancock P.J., Haskell K.M., Jones R.E., Kahana J.A., Kral A.M., Leander K., Lee L.L., Malinowski J., McAvoy E.M., Nahas D.D., Robinson R.G., Huber H.E. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 2005, 385:399-408.
108. Burke J.R., Pattoli M.A., Gregor K.R., Brassil P.J., MacMaster J.F., McIntyre K.W., Yang X., Iotzova V.S., Clarke W., Strnad J., Qiu Y., Zusi F.C. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J. Biol. Chem. 2003, 278:1450-1456.
109. Girdler F., Sessa F., Patercoli S., Villa F., Musacchio A., Taylor S. Molecular basis of drug resistance in aurora kinases. Chem. Biol. 2008, 15:552-562.
110. Ewart-Toland A., Dai Q., Gao Y.T., Nagase H., Dunlop M.G., Farrington S.M., Barnetson R.A., Anton-Culver H., Peel D., Ziogas A., Lin D., Miao X., Sun T., Ostrander E.A., Stanford J.L., Langlois M., Chan J.M., Yuan J., Harris C.C., Bowman E.D., Clayman G.L., Lippman S.M., Lee J.J., Zheng W., Balmain A. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 2005, 26:1368-1373.
111. Kimura M.T., Mori T., Conroy J., Nowak N.J., Satomi S., Tamai K., Nagase H. Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk. Cancer Res. 2005, 65:3548-3554.
112. Bibby R.A., Tang C., Faisal A., Drosopoulos K., Lubbe S., Houlston R., Bayliss R., Linardopoulos S. A cancer-associated aurora A mutant is mislocalized and misregulated due to loss of interaction with TPX2. J. Biol. Chem. 2009, 284:33177-33184.
113. Briassouli P., Chan F., Linardopoulos S. The N-terminal domain of the Aurora-A Phe-31 variant encodes an E3 ubiquitin ligase and mediates ubiquitination of IkappaBalpha. Hum. Mol. Genet. 2006, 15:3343-3350.
114. Girdler F., Gascoigne K.E., Eyers P.A., Hartmuth S., Crafter C., Foote K.M., Keen N.J., Taylor S.S. Validating Aurora B as an anti-cancer drug target. J. Cell Sci. 2006, 119:3664-3675.